somatostatin receptor ligand

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2016
012320142016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
T2-weighted MRI signal intensity of GH-secreting pituitary adenomas is gaining recognition as a marker of disease characteristics… (More)
  • figure 1
Is this relevant?
Review
2016
Review
2016
Somatostatin and dopamine receptors are expressed in normal and tumoral somatotroph cells. Upon receptor stimulation… (More)
  • table 1
Is this relevant?
Review
2016
Review
2016
Pasireotide (Signifor(®)) long-acting release (LAR) is a next-generation somatostatin receptor ligand (SRL) approved for… (More)
Is this relevant?
2016
2016
Pituitary gigantism is a rare condition caused by growth hormone secreting hypersecretion, usually by a pituitary tumor… (More)
  • figure 1
  • figure 2
Is this relevant?
2015
2015
BACKGROUND A novel oral octreotide formulation was tested for efficacy and safety in a phase III, multicenter, open-label, dose… (More)
  • table 1
  • table 3
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Review
2015
Review
2015
Somatostatin receptor ligands (octreotide and lanreotide) are currently first-line pharmacotherapy for patients with acromegaly… (More)
Is this relevant?
2014
2014
INTRODUCTION Biochemical efficacy of somatostatin receptor ligand (SRL) treatment in acromegaly is defined by metrics for GH and… (More)
Is this relevant?